This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer of the III-IV stages.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Disease-free survival
Timeframe: From enrollment through study completion, an average of 2 year
The frequency of adverse events
Timeframe: From date of first immunotherapy dose through 60 months, or date of last patient contact